Skip to main content
SRS 2025 Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Location/Live Stream
IRCAD
IRCAD
Le Palais de Congres
Le Palais de Congres
Live Streaming
Live Streaming

Uro Onc Course

Uro Onc Course

Wednesday, July 16, 2025
8:00 AM - 12:15 PM CEST
Location: IRCAD- Hirsch Auditorium

IRCAD

Presentations:

  • 8:00 AM - 8:05 AM CEST
    Introduction to the course and Welcome

    Faculty: Vipul R. Patel, MD – AdventHealth Global Robotics Institute

    Faculty: Brian Miles

    Faculty: Marcio Covas Moschovas – AdventHealth Global Robotics Institute

  • 8:05 AM - 8:15 AM CEST
    Current Literature on High-risk prostate cancer: Best articles of 2024/25 and current literature on High-risk pCa

    Speaker: Marcio Covas Moschovas – AdventHealth Global Robotics Institute

  • 8:15 AM - 8:25 AM CEST
    Prostate cancer screening and diagnosis: Genetic tests applications in High-risk PCa (Decipher, 4k, PHI, GPS, urinary markers, exosomes, etc). Do we have benefits? When should I order?

    Speaker: John Davis

  • 8:25 AM - 8:35 AM CEST
    Prostate cancer screening and diagnosis: Current status of MRI and PET Scan in High-Risk prostate cancer staging (PSMA, Axumin, Fluoride, etc)

    Speaker: Justin Emtage

  • 8:35 AM - 8:45 AM CEST
    Prostate cancer screening and diagnosis: Adverse pathology in PCa biopsy (cribriform, intraductal, small cell): implications on the treatment

    Speaker: Marcelo Orvieto

  • 8:45 AM - 8:50 AM CEST
    Prostate cancer screening and diagnosis: Q+A

    Panelist: Marcio Covas Moschovas – AdventHealth Global Robotics Institute

    Panelist: John Davis

    Panelist: Justin Emtage

    Panelist: Marcelo Orvieto, n/a – Department of Urology, Clínica Alemana, Santiago, Chile

  • 8:50 AM - 9:00 AM CEST
    High-Risk and Locally Advanced Prostate Cancer: Genomic test applications in high-risk and patients with family history of PCa: When should I use? Pre-Recorded lecture

    Speaker: Elena Efstathiou

  • 9:00 AM - 9:10 AM CEST
    High-Risk and Locally Advanced Prostate Cancer: Neoadjuvant Hormone deprivation therapy: where do we stand?

    Speaker: Justin Emtage

  • 9:10 AM - 9:20 AM CEST
    High-Risk and Locally Advanced Prostate Cancer: The role and extent of lymph node dissection in the PET-PSMA ERA

    Speaker: Karim Touijer

  • 9:20 AM - 9:30 AM CEST
    High-Risk and Locally Advanced Prostate Cancer: Radiation protocols in HR disease ( prostate RT vs. Prostate and pelvis vs. prostate lesion RT boost) Pre-Recorded lecture

    Speaker: Bridget Koontz

  • 9:30 AM - 9:40 AM CEST
    High-Risk and Locally Advanced Prostate Cancer: The role of Focal Therapy in High-grade prostate cancer. Should we do it?

    Speaker: Brian Miles

  • 9:40 AM - 9:50 AM CEST
    High-Risk and Locally Advanced Prostate Cancer: Surgical Margins Impacts and postoperative management in high-risk prostate cancer

    Speaker: Rafael Coelho

  • 9:50 AM - 10:00 AM CEST
    High-Risk and Locally Advanced Prostate Cancer: Neurosafe, Confocal and real time positive surgery margins evaluation. Where do we stand?

    Speaker: Chiara Sighniofli

  • 10:00 AM - 10:30 AM CEST
    High-Risk and Locally Advanced Prostate Cancer: Clinical cases discussion- Challenging cases of prostate cancer: experience from a high-volume referral center

    Speaker: Marcio Covas Moschovas – AdventHealth Global Robotics Institute

    Speaker: Chiara Sighniofli

    Speaker: Christian Wagner

  • 10:30 AM - 10:50 AM CEST
    Break
  • 10:50 AM - 11:00 AM CEST
    Recurrent Disease After Local Treatment: Applications of PSMA Pet in staging PCa recurrence. When should I order and how should I do the interpretation?
  • 11:00 AM - 11:10 AM CEST
    Recurrent Disease After Local Treatment: PSA persistence after surgery : medical oncologist approach (Pre-Recorded Lecture)

    Speaker: Guru Sonpavde

  • 11:10 AM - 11:20 AM CEST
    Recurrent Disease After Local Treatment: PSA persistence after surgery: when is the best time and optimal candidates to undergo Salvage RT

    Speaker: John Davis

  • 11:20 AM - 11:30 AM CEST
    Recurrent Disease After Local Treatment: Selecting the best salvage treatment after non-surgical treatment failure for localized prostate cancer? Surgery vs. RT vs. Ablation

    Speaker: Senthil Nathan

  • 11:30 AM - 11:40 AM CEST
    Recurrent Disease After Local Treatment: Managing PCa with lymph node recurrence: how to optimize results? Salvage Lymphadenectomy vs. RT protocols.

    Speaker: Anthony Costello

  • 11:40 AM - 11:50 AM CEST
    Oligometastatic disease: Current role of RT + Hormone deprivation in Oligometastatic disease. Should we use ADT in all candidates? Should we irradiate the metastasis as well?

    Speaker: Bridget Koontz

  • 11:50 AM - 12:00 PM CEST
    Oligometastatic disease: Current role of surgery in Oligometastatic disease

    Speaker: Bernardo Rocco

  • 12:00 PM - 12:15 PM CEST
    Urologic Oncology Q + A

    Panelist: John Davis

    Panelist: Senthil Nathan

    Panelist: Anthony Costello

    Panelist: Bernardo Rocco

  • 8:15 PM - 8:40 AM CEST
    Morning Moderators

    Moderator: Brian Miles

    Moderator: John Davis

    Moderator: Marcelo Orvieto, n/a – Department of Urology, Clínica Alemana, Santiago, Chile

    Moderator: Alejandro Rodriguez